Human anti-VEGFR-2/KDR antibodies
The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases, hyperproliferative disorders, and angiogenic disorders and can be used alone or in combination with other agents.
1. A nucleic acid encoding an antibody or antigen binding fragment thereof that binds to human VEGFR2, the antibody or antigen binding fragment thereof comprising a heavy chain variable domain, which comprises a CDR1H, a CDR2H, and a CDR3H sequence, and a light chain variable domain, which comprises a CDR1L, a CDR2L, and a CDR3L sequence wherein:
(i) the CDR1H sequence is GFTFSWYVMG (SEQ ID NO: 237);
(ii) the CDR2H sequence is SIYPQGGATSYADSVKG (SEQ ID NO: 238);
(iii) the CDR3H sequence is GNYFDY (SEQ ID NO: 241);
(iv) the CDR1L sequence is RASQSVSSNYFG (SEQ ID NO: 245);
(v) the CDR2L sequence is GASSRAT (SEQ ID NO: 246); and
(vi) the CDR3L sequence is QQFDSLPLT (SEQ ID NO: 247).
2. The nucleic acid of claim 1 , wherein the heavy chain variable domain has a sequence that is SEQ ID NO: 200, and wherein the light chain variable domain has a sequence that is SEQ ID NO: 204.
3. The nucleic acid of claim 1 , wherein the antibody or antigen binding fragment thereof has isotype IgG.
4. The nucleic acid of claim 1 , wherein the antibody or antigen binding fragment thereof is an scFv, Fv, Fab′, Fab, F(ab′)2, or diabody.
5. The nucleic acid of claim 1 , wherein the antibody or antigen binding fragment thereof binds to human VEGFR2 and murine VEGFR2.
6. The nucleic acid of claim 1 , wherein the heavy chain variable domain has a sequence that is at least 85% identical to the sequence of SEQ ID NO: 200, and wherein the light chain variable domain has a sequence that is at least 85% identical to the sequence of SEQ ID NO: 204.
7. A nucleic acid vector comprising the nucleic acid of claim 1 .
8. A prokaryotic or eukaryotic cell comprising the nucleic acid of claim 1 .